Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

3. Justifying its valuation with its outlook Eli Lilly's valuation might be a significant stumbling block for some investors. If the stock fails to meet the market's lofty expectations, its shares ...

Eli Lilly launches Mounjaro KwikPen in India, expanding weight-loss drug options and intensifying competition with Novo Nordisk.

Eli Lilly and Company (NYSE: LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants ...

Fueled by sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030, Evaluate projects.

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Lilly's new plant in North Carolina, which is the company's second in the state, uses a mix of automation and robotics to crank out injectable drugs.

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key ...

Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the most frequently ...

Market Implications: The ongoing study of LY3541860 could influence Eli Lilly’s stock performance and investor sentiment, particularly if the results show promise in treating rheumatoid arthritis.